New Kid on the Block: A First Look at the Clinical Use of Pitolisant for Narcolepsy

Main Article Content

Andrea Cuamatzi Castelan Castelan
Virginia Skiba
Luisa Bazan
Kenneth Moss
Meeta Singh
Christopher Drake
Philip Cheng

Abstract

Aims: Highlight pitolisant as an effective treatment for narcolepsy.

Case Report: We describe two patients treated with pitolisant. Patient A showed decreased daytime sleepiness and improved social functioning. Patient B struggled to find a dose that kept side effects at a minimum.

Discussion: This orphan drug has a unique mechanism of action, that combined with dosing flexibility allows for a treatment option that can better attend to individual differences in patient needs.

Conclusion: The use of pitolisant presents some benefits and challenges, nonetheless offering a promising treatment for narcolepsy.

Keywords:
Narcolepsy, pitolisant, excessive daytime sleepiness, histamine, histamine 3 receptor.

Article Details

How to Cite
Castelan, A. C. C., Skiba, V., Bazan, L., Moss, K., Singh, M., Drake, C., & Cheng, P. (2021). New Kid on the Block: A First Look at the Clinical Use of Pitolisant for Narcolepsy. International Journal of Medical and Pharmaceutical Case Reports, 14(1), 1-5. https://doi.org/10.9734/ijmpcr/2021/v14i130120
Section
Case Study

References

Teixeira VG, Faccenda JF, Douglas NJ. Functional status in patients with narcolepsy. Sleep Med. 2004;5(5):477-483.

Barateau L, Dauvilliers Y. Recent advances in treatment for narcolepsy. Ther Adv Neurol Disord. 2019;12: 1756286419875622.

Romigi, A, Vitrani G, Lo Giudice T, Centonze, D, Franco V. Profile of pitolisant in the management of narcolepsy: Design, development and place in therapy. Drug Design, Development and Therapy. 2018;12:2665–2675.

Dauvilliers Y, Bassetti C, Lammers GJ et al. Pitolisant versus placebo or modafinil in patients with narcolepsy: A double-blind, randomised trial. Lancet Neurol. 2013; 12(11):1068-75.

Uguen M, Perrin D, Belliard S et al. Preclinical evaluation of the abuse potential of Pitolisant, a histamine H₃ receptor inverse agonist/antagonist compared with Modafinil. Br J Pharmacol. 2013;169(3):632-44.

Szakacs Z, Dauvilliers Y, Mikhaylov V, et al. Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: A randomized, double-blind, placebo-controlled trial. Lancet Neurology. 2017; 16(3):200-207.

Setnik B, McDonnell M, Mills C, et al. Evaluation of the abuse potential of pitolisant, a selective H3-receptor antagonist/inverse agonist, for the treatment of adult patients with narcolepsy with or without cataplexy. Sleep. 2020; 43(4):zsz252.